Management of Poststroke Hyperglycemia : Results of the TEXAIS Randomized Clinical Trial
Journal article
Bladin, Christopher, Wah Cheung, Ngai, Dewey, Helen M., Churilov, Leonid, Middleton, Sandra Jane, Thijs, Vincent, Ekinci, Elif I, Levi, Chris, Lindley, Richard, Donnan, Geoffrey, Parsons, Mark William, Meretoja, Atte, Tiainen, Marjaana, Choi, Philip M C, Cordato, Dennis, Brown, Helen, Campbell, Bruce C V, Davis, Stephen, Cloud, Geoffrey, ... Fink, John. (2023). Management of Poststroke Hyperglycemia : Results of the TEXAIS Randomized Clinical Trial. Stroke. 54(12), pp. 2962-2971. https://doi.org/10.1161/STROKEAHA.123.044568
Authors | Bladin, Christopher, Wah Cheung, Ngai, Dewey, Helen M., Churilov, Leonid, Middleton, Sandra Jane, Thijs, Vincent, Ekinci, Elif I, Levi, Chris, Lindley, Richard, Donnan, Geoffrey, Parsons, Mark William, Meretoja, Atte, Tiainen, Marjaana, Choi, Philip M C, Cordato, Dennis, Brown, Helen, Campbell, Bruce C V, Davis, Stephen, Cloud, Geoffrey, Grimley, Rohan, Lee-Archer, Matthew, Ghia, Darshan, Sanders, Lauren, Markus, Romesh, Muller, Claire, Salvaris, Patrick, Wu, Teddy and Fink, John |
---|---|
Abstract | Hyperglycemia in acute ischemic stroke reduces the efficacy of stroke thrombolysis and thrombectomy, with worse clinical outcomes. Insulin-based therapies are difficult to implement and may cause hypoglycemia. We investigated whether exenatide, a GLP-1 (glucagon-like peptide-1) receptor agonist, would improve stroke outcomes, and control poststroke hyperglycemia with minimal hypoglycemia. Methods:The TEXAIS trial (Treatment With Exenatide in Acute Ischemic Stroke) was an international, multicenter, phase 2 prospective randomized clinical trial (PROBE [Prospective Randomized Open Blinded End-Point] design) enrolling adult patients with acute ischemic stroke ≤9 hours of stroke onset to receive exenatide (5 µg BID subcutaneous injection) or standard care for 5 days, or until hospital discharge (whichever sooner). The primary outcome (intention to treat) was the proportion of patients with ≥8-point improvement in National Institutes of Health Stroke Scale score (or National Institutes of Health Stroke Scale scores 0–1) at 7 days poststroke. Safety outcomes included death, episodes of hyperglycemia, hypoglycemia, and adverse event. Results:From April 2016 to June 2021, 350 patients were randomized (exenatide, n=177, standard care, n=173). Median age, 71 years (interquartile range, 62–79), median National Institutes of Health Stroke Scale score, 4 (interquartile range, 2–8). Planned recruitment (n=528) was stopped early due to COVID-19 disruptions and funding constraints. The primary outcome was achieved in 97 of 171 (56.7%) in the standard care group versus 104 of 170 (61.2%) in the exenatide group (adjusted odds ratio, 1.22 [95% CI, 0.79–1.88]; P=0.38). No differences in secondary outcomes were observed. The per-patient mean daily frequency of hyperglycemia was significantly less in the exenatide group across all quartiles. No episodes of hypoglycemia were recorded over the treatment period. Adverse events of mild nausea and vomiting occurred in 6 (3.5%) exenatide patients versus 0 (0%) standard care with no withdrawal. Conclusions:Treatment with exenatide did not reduce neurological impairment at 7 days in patients with acute ischemic stroke. Exenatide did significantly reduce the frequency of hyperglycemic events, without hypoglycemia, and was safe to use. Larger acute stroke trials using GLP-1 agonists such as exenatide should be considered. Registration:URL: www.australianclinicaltrials.gov.au; Unique identifier: ACTRN12617000409370. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03287076. |
Keywords | Exenatide; Hyperglycemia; Ischemic stroke; Stroke; Thrombectomy |
Year | 01 Jan 2023 |
Journal | Stroke |
Journal citation | 54 (12), pp. 2962-2971 |
Publisher | Lippincott Williams & Wilkins |
ISSN | 1524-4628 |
Digital Object Identifier (DOI) | https://doi.org/10.1161/STROKEAHA.123.044568 |
Web address (URL) | https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.044568 |
Open access | Published as ‘gold’ (paid) open access |
Research or scholarly | Research |
Page range | 2962-2971 |
Publisher's version | License File Access Level Open |
Output status | Published |
Publication dates | |
23 Nov 2023 | |
Publication process dates | |
Accepted | Nov 2023 |
Deposited | 09 Apr 2024 |
Grant ID | 1126070 |
Additional information | The TEXAIS (Treatment With Exenatide in Acute Ischemic Stroke) was supported by research grant 1126070 from the National Health and Medical Research Council of Australia. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Material support from Medtronic in the use of Medtronic iPro2 Professional Continuous Glucose Monitors. |
© 2023 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. | |
Place of publication | United States |
https://acuresearchbank.acu.edu.au/item/904x9/management-of-poststroke-hyperglycemia-results-of-the-texais-randomized-clinical-trial
Download files
Publisher's version
OA_Middleton_23_Management of poststroke hyperglycemia Results of.pdf | |
License: CC BY 4.0 | |
File access level: Open |
52
total views25
total downloads6
views this month3
downloads this month